Gilead says its twice-yearly shot cut HIV infections by 96% in trial

The data sets the stage for likely approval of Gilead's lenacapavir for HIV prevention.

...

Montana's hot housing market heats up critical Senate race

1 week ago

DJT shares soar as Trump says 'I'm not selling' stake

1 week ago

Harris pledges to 'earn the vote' of Black men, as Trump makes gains

1 week ago

Harris victory seen as most likely election outcome, according to CNBC Fed Survey

1 week ago

Biden’s student debt forgiveness plan to remain blocked, federal judge orders

1 week ago